Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
0.9226
-0.0774 (-7.74%)
At close: Nov 20, 2026, 4:00 PM EST
0.9300
+0.0074 (0.80%)
After-hours: Nov 20, 2026, 7:45 PM EST
Aardvark Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Aardvark Therapeutics stock has a consensus rating of "Hold" and an average price target of $4.00. The average 1-year stock price forecast is 333.56% higher than the current stock price, while the lowest is $1.50 (+62.58%) and the highest is $10 (+983.89%).
Price Target: $4.00 (+333.56%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Aardvark Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 5 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 4 | 4 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 12 | 12 | 12 | 12 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $2 | Hold | Maintains | $2 | +116.78% | Nov 17, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $2.5 | Hold | Maintains | $2.5 | +170.97% | Nov 13, 2026 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $3 | Sell | Maintains | $3 | +225.17% | Nov 13, 2026 |
| Raymond James | Raymond James | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Nov 4, 2026 |
| Oppenheimer | Oppenheimer | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Oct 26, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.33
from -2.93
EPS Next Year
-2.34
from -3.33
EPS and Forward PE are based on non-GAAP adjusted numbers.